| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2021: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to evaluate radiosensitivity in patients receiving preoperative chemoradiation for rectal cancer and to develop an index to predict treatment outcomes and adverse events. We prospectively enrolled 28 patients with rectal cancer and evaluated the association between radiosensitivity and treatment outcomes and adverse events. Three of the 28 patients achieved pathologic complete response, and the γH2AX focus counts in peripheral blood lymphocytes tended to be high in these three patients after 45 Gy irradiation. In terms of adverse events, there was a significant correlation between the number of chromosome aberrations in the peripheral blood lymphocytes and the severity of adverse events. A new index for predicting treatment outcomes and adverse events based on radiosensitivity was established.
Translated with www.DeepL.com/Translator (free version)
|
